Sangeeta Kashyap

Dec 4, 2024 | healio.com | Erik Swain |Richard Smith |Sangeeta Kashyap

Perspective Back to Top Sangeeta Kashyap, MD I’m not surprised by these results since dual incretin agonists like tirzepatide offer a stronger, more comprehensive effect on weight loss than GLP-1 agonists like semaglutide because they target both GLP-1 and GIP receptors, providing synergistic benefits in appetite suppression, fat metabolism and insulin sensitivity.

Jul 24, 2024 | healio.com | Regina Schaffer |Erik Swain |Sangeeta Kashyap |Michael Hall

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Data show a potent class of obesity drugs and bariatric surgery each reduce blood pressure along with body weight. An “obesity first” strategy may reduce or eliminate the need for antihypertensive medicines.